SWOG clinical trial number
SWOG-9208

Health Status and Quality of Life (QL) in Patients with Early Stage Hodgkin's Disease: A companion study to SWOG-9133, Ancillary

Closed
Phase
Published
Abbreviated Title
Quality of Life Companion study - Hodgkin's
Activated
04/15/1994
Closed
04/24/2000

Research committees

Lymphoma

Eligibility Criteria Expand/Collapse

Patients entered on SWOG-9133; Pts. able to read and understand English.

Publication Information Expand/Collapse

2017

Seven year follow-up for energy/vitality outcomes in early stage hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

C Moinpour;J Unger;P Ganz;T Wang;A Kornblith;E Gaynor;MA Bowers;S Balcerzak;G Gatti Gunderson;Mark Kaminski;H Erba;O Press;RI Fisher Journal of Cancer Survivorship:Research and Practice, 2017 Feb;11(1):32-40; 2016 Jul 12 [Epub ahead of print]

PMid: PMID27405732 | PMC number: PMC5233644

2007

Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions

PA Ganz;CC Gotay Journal of Clinical Oncology 25(32):5063-9

PMid: PMID17991922

2004

Predictors of vitality (energy/fatigue) in early stage hodgkin's disease (HD): results from Southwest Oncology Group (SWOG) study 9133

PA Ganz;CM Moinpour;S McCoy;DK Pauler;OW Press;RI Fisher Proc of the American Society of Clinical Oncology 23:567 (#6546)

2003

Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group study 9133

PA Ganz;CM Moinpour;DK Pauler;AB Kornblith;ER Gaynor;SP Balcerzak;GS Gatti;HP Erba;S McCoy;OW Press;RI Fisher Journal of Clinical Oncology 21(18):3512-3519

2000

Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience

CC Gotay;CM Moinpour;S Moody-Thomas;ER Gritz;KS Albain;E DeAntoni;L Hansen;PA Ganz Journal of the National Cancer Institute 92(17):1381-1387

Other Clinical Trials

SWOG Clinical Trial Number
S2506

MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
74%
Open
Phase